Form 4: Corcept Therapeutics Officer Lyon Reports Stock Transactions

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, reports the acquisition and disposal of company stock, including transactions under a 10b5-1 plan and a purchase plan.

Summary

• On June 3, 2024, Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, reported transactions involving Corcept Therapeutics common stock.
• Lyon exercised stock options to acquire 5,000 shares at $11.35 per share.
• He then sold 5,000 shares at a weighted average price of $30.1832 per share, with individual sale prices ranging from $30.17 to $30.21.
• 488 shares were withheld by the issuer to satisfy tax obligations related to vesting restricted stock units, calculated using a price of $30.17.
• Lyon also acquired 1,232 shares under a purchase plan at $31.3 per share and received 1,232 shares underlying unvested restricted stock awards under the same plan.
• Following these transactions, Lyon directly owns 9,290 shares of Corcept Therapeutics common stock, which includes shares underlying unvested restricted stock awards.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions by an officer, with no clear positive or negative implications for the company's overall prospects.

Positives

• The exercise of stock options and subsequent sale at a higher price indicates Lyon's belief in the company's value.
• The purchase of shares under the purchase plan further demonstrates his confidence in Corcept Therapeutics.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of restricted stock awards and the terms of the purchase plan suggest continued alignment of Lyon's interests with the company's performance.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the trading activities of company insiders. This filing indicates that Lyon is actively managing his equity stake in Corcept Therapeutics.

Comparison to Industry Standards

• Insider transactions are common in publicly traded companies, and the details of these transactions are closely monitored by investors.
• The use of 10b5-1 plans is a standard practice to allow insiders to trade company stock without being accused of trading on non-public information.
• The vesting schedules of restricted stock awards are typical for executive compensation packages, aligning management's interests with long-term shareholder value.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by increasing the number of shares available in the market.
• The vesting of restricted stock awards incentivizes the Reporting Person to remain with the company and contribute to its success.

Key Dates